RFA-CA-20-040 – Aging, Cancer-Initiating Cells, and Cancer Development (U01 Clinical Trial Not Allowed)

For those who might be interested in submitting an application to RFA-CA-20-040 in which NIA is an equal partner, please see this notice.

Informational Webinar scheduled for Sep 18.

Questions ahead of Webinar due Sep 14.

The lead contact for NIA is Candace Kerr, Ph.D.
Email: [email protected]

Pre-Application Webinar for RFA-CA-20-040, Aging, Cancer-Initiating Cells, and Cancer Development (U01 Clinical Trial Not Allowed)

Notice Number: NOT-CA-20-105

Key Dates

Release Date: September 8, 2020

Related Announcements

RFA-CA-20-040 – Aging, Cancer-Initiating Cells, and Cancer Development (U01 Clinical Trial Not Allowed)

Issued by National Cancer Institute (NCI)

Purpose

The National Cancer Institute (NCI) will hold a pre-application webinar on September 18, 2020, from 1:00 – 2:00 PM (ET) for the Funding Opportunity Announcement (FOA) RFA-CA-20-040 titled “Aging, Cancer-Initiating Cells, and Cancer Development (U01 Clinical Trial Not Allowed)”.

NCI and National Institute on Aging (NIA) staff members involved in the FOA will provide a brief overview of the RFA-CA-20-040 for potential applicants by explaining the goals and objectives for the FOA, as well as answering questions from webinar attendees.

Please submit questions by September 14, 2020 to [email protected]. Attendees will also be able to submit questions during the webinar. Questions submitted early will be answered first.

Join the webinar or copy and paste the following Webex link into your browser: https://cbiit.webex.com/cbiit/j.php?MTID=m6a7b73daaa815f0601174dbebb02345c

Participation in this webinar, although encouraged, is optional and is not required for the submission of an application in response to RFA-CA-20-040. A document highlighting frequently asked questions and corresponding answers will be posted to the NCI Division of Cancer Biology FOA website following the webinar.

Please direct all inquiries to:

Margaret Klauzinska, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-5181
Email: [email protected]

Candace Kerr, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-827-4474
Email: [email protected]

NIA Advisory Council Meeting September 9th

Join us for the Open Session of the NIA Advisory Council Meeting on September 9th from 10am – 1pm ET

To view: http://videocast.nih.gov

Agenda

SEPTEMBER 9

10:00 a.m. to adjournment – This portion of the meeting is open to the Public.

This meeting will be videocast from 10:00 a.m. to 1:00 p.m.:  http://videocast.nih.gov

10:00 to 10:30 a.m.

  1. Call to Order———————————————————— Dr. Richard Hodes

10:30 to 10:45 a.m.
II.  Report:  Task Force on Minority Aging Research
Dr J Taylor Harden

10:45 to 11:45 a.m.

III. Report:  Working Group on Program

Dr. Stephen Kritchevsky

11:45 to 12:00 p.m.

IV. A Word from Retiring Members

Dr. Richard Hodes

David Bennett, J Taylor Harden, David Holtzman, Stephen Kritchevsky, and Sue Peschin

12:00 to 12:30 p.m.

V.  Council Guest Speaker

Dr. Eliseo J. Pérez-Stable

Director, National Institute on Minority Health and Health Disparities “Health Disparities Challenges in Aging Research”

12:30 to 1:00 p.m.                                             

VI. Council Guest Speaker

Dr. Monica A. Driscoll

Professor, Department of Molecular Biology and Biochemistry Rutgers, the State University of New Jersey

“Neurons Put Out the Trash: A Novel Facet of Proteostasis and Mitochondrial Quality Control”

1:00 p.m.

Adjournment

NIH Inclusion Across Lifespan-II Workshop 9/2/2020

The NIH Inclusion Across Lifespan-II Workshop is happening TOMORROW, starting at 11am Eastern. 

For more information, visit the IAL-II website; in addition, we’ve provided some key details and links below.

To participate tomorrow, click here: https://videocast.nih.gov/live.asp?live=38384&preview=1.

Pre-recorded overviews of topic areas from some of the workshop panel co-chairs here: https://go.usa.gov/xGqGE.

Here’s an overview of the topics that will be covered:

Topic Area 1: Inclusion/exclusion criteria

Panel co-chairs:

Summary:

The study population defined by the eligibility criteria should be representative of the population of people with the condition being studied. The inclusion and exclusion criteria should be objective and written in clear, concise language, and investigators should provide a scientific justification for each criterion. The co-chairs will discuss this topic with specific considerations for the pediatric and older adult perspectives.

Topic Area 2: Study design and metrics

Panel co-chairs:

  • Jerry Gurwitz, M.D., University of Massachusetts Medical School
  • Peter Peduzzi, Ph.D., Yale University School of Medicine

PLEASE NOTE: Topic area 2: Study design and metrics does not have pre-recorded videos to view.

Summary:

The study design and metrics of a clinical trial should be constructed in a way to be more inclusive across all ages, using input from the entire study population. Here we will examine challenges that investigators face when designing studies and how these challenges can impact clinical trials.

Topic Area 3: Recruitment, enrollment, and retention

Panel co-chairs:

Summary:

Ensuring appropriate representation of children and older adults in clinical trials goes beyond the inclusion criteria — additional consideration is needed to design effective methods to identify, enroll, and retain children and older adults in clinical studies and trials. The co-chairs will examine the pediatric and geriatric considerations for recruitment and retention with emphasis on special populations.

Topic Area 4: Data analysis and study interpretation

Panel co-chairs:

Summary:

Appropriate data analysis and interpretation is critical to the synthesis of trial evidence and its application in treating patients. This includes careful consideration of certain sub-populations in the analysis, including children and older adults. The study of specific sub-populations must be considered throughout the process, beginning with study design, and extending to data analysis, interpretation, and dissemination. With increases in inclusion of children and older adults in clinical studies, it is critical to develop data analysis plans that ensure appropriate, relevant, and meaningful study conclusions.

COVID: Opportunities and Obstacles in Aging Research and Caregiving

Please join the Friends of the National Institute on Aging (FoNIA) and our distinguished panelists on Thursday, August 6, 2020, 1:00 pm – 2:00 pm, EDT for a webinar on COVID: Opportunities and Obstacles in Aging Research and Caregiving which will explore the nexus between the COVID-19 virus and older adults.  Register here. Specifically, our three panelists will discuss: 

  • What does data around COVID tells us about existing racial, economic and geographical health disparities;∙
  • How aging research can be more inclusive in light of COVID exposed disparities;
  • Opportunities to study care needs of older adults and their caregivers before, during and after the COVID-19 pandemic; and
  • How aging impacts the effectiveness of potential COVID treatments and vaccines.
Panelists:

Roland J. Thorpe, Jr., PhD
Professor, Health Behavior and Society
Johns Hopkins University
 
Vicki A. Freedman, PhD
Research Professor, Institute for Social Research
Director, Michigan Center on the Demography of Aging
University of Michigan
 
Matt R. Kaeberlein, PhD
Professor, Department of Pathology
University of Washington

Register Here

NIA-supported research has shown that the APOE gene may play a role in the breakdown of the blood-brain barrier in Alzheimer’s disease

NIA-supported research has shown that the APOE gene may play a role in the breakdown of the blood-brain barrier in Alzheimer’s disease.  The blood-brain barrier (BBB) is a semi-permeable barrier which facilitates the selective entry of materials into the brain from the adjacent blood supply.  Prior studies suggest that the BBB breaks down in AD, and researchers in the current study wanted to understand if APOE genetic status might influence BBB breakdown.  245 participants were recruited to undergo a specific type of magnetic resonance imaging (MRI) which can identify leakiness in the BBB.  Of the 245 participants, those who had one or more copies of the high-risk APOE ε4 allele showed increased breakdown of the BBB relative to those with two copies of the APOE ε3 allele.  In addition, the researchers also tracked damage to pericytes, or cells which help to maintain the BBB, and they saw that pericyte damage predicted cognitive decline and increased inflammatory activity in APOE ε4+ participants.  Notably, BBB breakdown appeared to occur independently from the accumulation of amyloid-beta and tau proteins, two known AD biomarkers, suggesting that it may be an independent contributor to cognitive decline, dementia, and AD.  This study was published in Nature.